Evidence map›Paper›PMID 35631596›Full record

ArticlePharmaceutics2022

Yuka Muranaka, Asuka Mizutani, Masato Kobayashi, Koya Nakamoto, Miki Matsue, Fumika Takagi, Kenichi Okazaki, Kodai Nishi, Kana Yamazaki, Ryuichi Nishii and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Potential Application of the Myocardial Scintigraphy Agent [International journal of molecular sciences · 2024
    Article
  2. SPECT Imaging ofPharmaceutics · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Yuka MuranakaDivision of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.
Asuka MizutaniFaculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.
Masato KobayashiFaculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.ORCID 0000-0001-5172-2626
Koya NakamotoDivision of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.
Miki MatsueIshikawa Prefectural Institute of Public Health and Environmental Science, 1-11, Taiyogaoka, Kanazawa 920-1154, Japan.
Fumika TakagiLaboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka 561-0825, Japan.
Kenichi OkazakiLaboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka 561-0825, Japan.
Kodai NishiDepartment of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.ORCID 0000-0002-4919-7639
Kana YamazakiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage, Chiba 263-8555, Japan.
Ryuichi NishiiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage, Chiba 263-8555, Japan.ORCID 0000-0002-2096-4611
Naoto ShikanoDepartment of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, 4669-2 Ami, Inashiki 300-0394, Japan.
Shigefumi OkamotoFaculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.ORCID 0000-0001-9359-380X
Hideki MakiLaboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka 561-0825, Japan.
Keiichi KawaiDivision of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.
Kanazawa University · JPShionogi (Japan) · JPNational Institutes for Quantum Science and Technology · JPIbaraki Prefectural University of Health Sciences · JPNagasaki University · JP

Funding

Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science No. 18K19508, No. 18K07747 and No. 21H02865SHIONOGI & Co., Ltd. 01
6 · The paper itself

Abstract

In this study, we evaluated the use of 15-(4-

Indexed as

123I-BMIPPbacterial imagingbacterial infectionnuclear medicine imagingSPECT

Identifiers

PMID35631596
PMCPMC9143722
OpenAlexW4229374954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.